Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations

Dennis C. Turk(University of Washington), Kerry Wolf, Richard Malamut(Teva Pharmaceuticals (Czechia)), Roger D. Weiss(McLean Hospital), Petra Jacobs(National Institute on Drug Abuse), Christine Rauschkolb(Johnson & Johnson (United States)), Lynn R. Webster(Adherent Technologies (United States)), Bob A. Rappaport, Deborah B. Leiderman(CNS Research (United States)), Nabarun Dasgupta(University of North Carolina at Chapel Hill), Richard A. Denisco(National Institute on Drug Abuse), John D. Markman(University of Rochester), Richard C. Dart(Washington Poison Center), Jennifer Sharpe Potter(The University of Texas at San Antonio Health Science Center), Robert H. Dworkin(University of Rochester Medical Center), Alec O'connor(University of Rochester), Robert Lubran(Johns Hopkins University), Edgar H. Adams(Covance (United States)), Amina Chaudhry(Johns Hopkins University), Laurie B. Burke(Center for Drug Evaluation and Research), Carl L. Roland(Pfizer (United States)), Sandra D. Comer(New York Psychoanalytic Society and Institute), John S. Brownstein(Boston Children's Hospital), Srinivasa N. Raja(Johns Hopkins University), Pamela Pierce Palmer(AcelRx Pharmaceuticals (United States)), Sarah Peirce‐Sandner(University of Rochester), Penney Cowan(American Chronic Pain Association), Harry Ahdieh(Endo Pharmaceuticals (United States)), Edward Michna(Brigham and Women's Hospital), Nathaniel P. Katz(Wellesley College), Michael Klein(Marymount University), James P. Zacny(University of Chicago)
Cited by 32


Related Papers